Trial Profile

A Phase I-II Study of Lapatinib and Docetaxel as Neoadjuvant Treatment for HER-2 Positive Locally Advanced/Inflammatory or Large Operable Breast Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 31 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Lapatinib (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Trastuzumab
Indications Advanced breast cancer; Early breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms LAPATAX

Most Recent Events

30 May 2019 This trial has been completed in France, according to European Clinical Trials Database.
18 Nov 2015 Accrual to date is 78% according to United Kingdom Clinical Research Network record.
20 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com